Replacement Therapy · Episode 8 of 8 · 22 min
The Ones Who Were Told No
Premature ovarian insufficiency affects an estimated three to four percent of women, and about 300,000 American women a year lose both ovaries with a hysterectomy. For them estrogen is literal replacement, yet a generation was refused it on the strength of a trial whose average participant was sixty-three. The episode covers what absence costs, what guidelines say, and the FDA's February 2026 reversal.
Who's who
- Walter RoccaMayo Clinic researcher who linked early oophorectomy to cognitive and parkinsonism risk
- Martin MakaryFDA Commissioner who convened the 2025 panel and approved label changes
- Robert F. Kennedy Jr.+2 more episodesHHS Secretary who announced the boxed-warning action
- Adriane Fugh-Berman+1 more episodeGeorgetown pharmacologist who called the 2025 panel theater
- Jen GunterGynecologist who objected that the panel lacked methodologists and oncologists
- Steven J. FleishmanACOG president who welcomed the outcome
- JoAnn PinkertonClinician at the 2025 panel who argued the warning was unsupported
Where it happens
- United States+16 more episodesWhere roughly 300,000 women a year have both ovaries removed
Timeline
- 2002Women's Health Initiative combined arm stopped; hormone use falls by about half
- 2013Nurses' Health Study reports higher mortality after oophorectomy at hysterectomy
- 2024WHI investigators say findings should not be extrapolated to premature or early menopause
- July 17, 2025FDA convenes an informal expert panel on menopausal hormone therapy
- November 10, 2025HHS and FDA announce boxed-warning removal
- February 12, 2026FDA approves labeling changes for six products
Still debated
The FDA's decision was right in outcome but reached by an informal panel that the American College of Obstetricians and Gynecologists had asked it not to rely on. Evidence is less settled for breast cancer survivors, and the boxed warning alone cannot be shown to have caused the treatment gap.
